Archival Report| Volume 71, ISSUE 8, P714-724, April 15, 2012

Download started.


β-Arrestin2 Regulates Cannabinoid CB1 Receptor Signaling and Adaptation in a Central Nervous System Region–Dependent Manner


      Cannabinoid CB1 receptors (CB1Rs) mediate the effects of ▵9-tetrahydrocannabinol (THC), the psychoactive component in marijuana. Repeated THC administration produces tolerance and dependence, which limit therapeutic development. Moreover, THC produces motor and psychoactive side effects. β-arrestin2 mediates receptor desensitization, internalization, and signaling, but its role in these CB1R effects and receptor regulation is unclear.


      CB1R signaling and behaviors (antinociception, hypothermia, catalepsy) were assessed in β-arrestin2-knockout (βarr2-KO) and wild-type mice after THC administration. Cannabinoid-stimulated [35S]GTPγS and [3H]ligand autoradiography were assessed by statistical parametric mapping and region-of-interest analysis.


      β-arrestin2 deletion increased CB1R-mediated G-protein activity in subregions of the cortex but did not affect CB1R binding, in vehicle-treated mice. βarr2-KO mice exhibited enhanced acute THC-mediated antinociception and hypothermia, with no difference in catalepsy. After repeated THC administration, βarr2-KO mice showed reduced CB1R desensitization and/or downregulation in cerebellum, caudal periaqueductal gray, and spinal cord and attenuated tolerance to THC-mediated antinociception. In contrast, greater desensitization was found in hypothalamus, cortex, globus pallidus, and substantia nigra of βarr2-KO compared with wild-type mice. Enhanced tolerance to THC-induced catalepsy was observed in βarr2-KO mice.


      β-arrestin2 regulation of CB1R signaling following acute and repeated THC administration was region-specific, and results suggest that multiple, overlapping mechanisms regulate CB1Rs. The observations that βarr2-KO mice display enhanced antinociceptive responses to acute THC and decreased tolerance to the antinociceptive effects of the drug, yet enhanced tolerance to catalepsy, suggest that development of cannabinoid drugs that minimize CB1R interactions with β-arrestin2 might produce improved cannabinoid analgesics with reduced motor suppression.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Herkenham M.
        • Lynn A.B.
        • Johnson M.R.
        • Melvin L.S.
        • de Costa B.R.
        • Rice K.C.
        Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study.
        J Neurosci. 1991; 11: 563-583
        • Zimmer A.
        • Zimmer A.M.
        • Hohmann A.G.
        • Herkenham M.
        • Bonner T.I.
        Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.
        Proc Natl Acad Sci U S A. 1999; 96: 5780-5785
        • Pertwee R.G.
        The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.
        AAPS J. 2005; 7: E625-E654
        • Lichtman A.H.
        • Martin B.R.
        Cannabinoid tolerance and dependence.
        Handb Exp Pharmacol. 2005; : 691-717
        • Sim-Selley L.J.
        Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids.
        Crit Rev Neurobiol. 2003; 15: 91-119
        • Howlett A.C.
        • Barth F.
        • Bonner T.I.
        • Cabral G.
        • Casellas P.
        • Devane W.A.
        • et al.
        International Union of Pharmacology.
        Pharmacol Rev. 2002; 54: 161-202
        • Sim L.J.
        • Hampson R.E.
        • Deadwyler S.A.
        • Childers S.R.
        Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
        J Neurosci. 1996; 16: 8057-8066
        • Jin W.
        • Brown S.
        • Roche J.P.
        • Hsieh C.
        • Celver J.P.
        • Kovoor A.
        • et al.
        Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization.
        J Neurosci. 1999; 19: 3773-3780
        • Oviedo A.
        • Glowa J.
        • Herkenham M.
        Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study.
        Brain Res. 1993; 616: 293-302
        • Sim-Selley L.J.
        • Schechter N.S.
        • Rorrer W.K.
        • Dalton G.D.
        • Hernandez J.
        • Martin B.R.
        • et al.
        Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration.
        Mol Pharmacol. 2006; 70: 986-996
        • Gainetdinov R.R.
        • Premont R.T.
        • Bohn L.M.
        • Lefkowitz R.J.
        • Caron M.G.
        Desensitization of G protein-coupled receptors and neuronal functions.
        Annu Rev Neurosci. 2004; 27: 107-144
        • Attramadal H.
        • Arriza J.L.
        • Aoki C.
        • Dawson T.M.
        • Codina J.
        • Kwatra M.M.
        • et al.
        Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family.
        J Biol Chem. 1992; 267: 17882-17890
        • Kouznetsova M.
        • Kelley B.
        • Shen M.
        • Thayer S.A.
        Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture.
        Mol Pharmacol. 2002; 61: 477-485
        • Tsou K.
        • Brown S.
        • Sanudo-Pena M.C.
        • Mackie K.
        • Walker J.M.
        Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.
        Neuroscience. 1998; 83: 393-411
        • Bohn L.M.
        • Lefkowitz R.J.
        • Gainetdinov R.R.
        • Peppel K.
        • Caron M.G.
        • Lin F.T.
        Enhanced morphine analgesia in mice lacking beta-arrestin 2.
        Science. 1999; 286: 2495-2498
        • Schmid C.L.
        • Bohn L.M.
        Physiological and pharmacological implications of beta-arrestin regulation.
        Pharmacol Ther. 2009; 121: 285-293
        • Breivogel C.S.
        • Lambert J.M.
        • Gerfin S.
        • Huffman J.W.
        • Razdan R.K.
        Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 –/– mice.
        Behavioural pharmacology. 2008; 19: 298-307
        • Nguyen P.T.
        • Selley D.E.
        • Sim-Selley L.J.
        Statistical parametric mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain.
        Neuroimage. 2010; 52: 1243-1251
        • Bohn L.M.
        • Lefkowitz R.J.
        • Caron M.G.
        Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.
        J Neurosci. 2002; 22: 10494-10500
        • Pertwee R.G.
        The ring test: A quantitative method for assessing the “cataleptic” effect of cannabis in mice.
        Br J Pharmacol. 1972; 46: 753-763
        • McKinney D.L.
        • Cassidy M.P.
        • Collier L.M.
        • Martin B.R.
        • Wiley J.L.
        • Selley D.E.
        • et al.
        Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.
        J Pharmacol Exp Ther. 2008; 324: 664-673
        • Moise A.M.
        • Eisenstein S.A.
        • Astarita G.
        • Piomelli D.
        • Hohmann A.G.
        An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters.
        Psychopharmacology (Berl). 2008; 200: 333-346
        • Nguyen P.T.
        • Holschneider D.P.
        • Maarek J.M.
        • Yang J.
        • Mandelkern M.A.
        Statistical parametric mapping applied to an autoradiographic study of cerebral activation during treadmill walking in rats.
        Neuroimage. 2004; 23: 252-259
        • Lichtman A.H.
        • Cook S.A.
        • Martin B.R.
        Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
        J Pharmacol Exp Ther. 1996; 276: 585-593
        • Pertwee R.G.
        • Wickens A.P.
        Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids.
        Neuropharmacology. 1991; 30: 237-244
        • Rawls S.M.
        • Cabassa J.
        • Geller E.B.
        • Adler M.W.
        CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
        J Pharmacol Exp Ther. 2002; 301: 963-968
        • Smith P.B.
        • Martin B.R.
        Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia.
        Brain Res. 1992; 578: 8-12
        • Lichtman A.H.
        • Martin B.R.
        Spinal and supraspinal components of cannabinoid-induced antinociception.
        J Pharmacol Exp Ther. 1991; 258: 517-523
        • Bohn L.M.
        • Gainetdinov R.R.
        • Lin F.T.
        • Lefkowitz R.J.
        • Caron M.G.
        Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.
        Nature. 2000; 408: 720-723
        • Bohn L.M.
        • Dykstra L.A.
        • Lefkowitz R.J.
        • Caron M.G.
        • Barak L.S.
        Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery.
        Mol Pharmacol. 2004; 66: 106-112
        • Raehal K.M.
        • Bohn L.M.
        The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics.
        Neuropharmacology. 2011; 60: 58-65
        • Leterrier C.
        • Bonnard D.
        • Carrel D.
        • Rossier J.
        • Lenkei Z.
        Constitutive endocytic cycle of the CB1 cannabinoid receptor.
        J Biol Chem. 2004; 279: 36013-36021
        • Leterrier C.
        • Laine J.
        • Darmon M.
        • Boudin H.
        • Rossier J.
        • Lenkei Z.
        Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors.
        J Neurosci. 2006; 26: 3141-3153
        • McDonald N.A.
        • Henstridge C.M.
        • Connolly C.N.
        • Irving A.J.
        An essential role for constitutive endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid receptor.
        Mol Pharmacol. 2007; 71: 976-984
      1. Grimsey NL, Graham ES, Dragunow M, Glass M Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: Implications for therapeutics. Biochem Pharmacol 80:1050–1062.

        • Lein E.S.
        • Hawrylycz M.J.
        • Ao N.
        • Ayres M.
        • Bensinger A.
        • Bernard A.
        • et al.
        Genome-wide atlas of gene expression in the adult mouse brain.
        Nature. 2007; 445: 168-176
        • Breivogel C.S.
        • Childers S.R.
        • Deadwyler S.A.
        • Hampson R.E.
        • Vogt L.J.
        • Sim-Selley L.J.
        Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain.
        J Neurochem. 1999; 73: 2447-2459
        • Gurevich E.V.
        • Benovic J.L.
        • Gurevich V.V.
        Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development.
        Neuroscience. 2002; 109: 421-436
        • Conner D.A.
        • Mathier M.A.
        • Mortensen R.M.
        • Christe M.
        • Vatner S.F.
        • Seidman C.E.
        • et al.
        beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation.
        Circ Res. 1997; 81: 1021-1026
        • Huang C.C.
        • Chen Y.L.
        • Lo S.W.
        • Hsu K.S.
        Activation of cAMP-dependent protein kinase suppresses the presynaptic cannabinoid inhibition of glutamatergic transmission at corticostriatal synapses.
        Mol Pharmacol. 2002; 61: 578-585
        • Bass C.E.
        • Welch S.P.
        • Martin B.R.
        Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors.
        Eur J Pharmacol. 2004; 496: 99-108
        • Lee M.C.
        • Smith F.L.
        • Stevens D.L.
        • Welch S.P.
        The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol.
        J Pharmacol Exp Ther. 2003; 305: 593-599
        • Garcia D.E.
        • Brown S.
        • Hille B.
        • Mackie K.
        Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor.
        J Neurosci. 1998; 18: 2834-2841
        • Rubino T.
        • Forlani G.
        • Vigano D.
        • Zippel R.
        • Parolaro D.
        Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment.
        Mol Cell Neurosci. 2004; 25: 355-362
        • Rubino T.
        • Forlani G.
        • Vigano D.
        • Zippel R.
        • Parolaro D.
        Ras/ERK signalling in cannabinoid tolerance: From behaviour to cellular aspects.
        J Neurochem. 2005; 93: 984-991
        • Tappe-Theodor A.
        • Agarwal N.
        • Katona I.
        • Rubino T.
        • Martini L.
        • Swiercz J.
        • et al.
        A molecular basis of analgesic tolerance to cannabinoids.
        J Neurosci. 2007; 27: 4165-4177